Lenalidomide Orion 5 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide orion 5 mg kapseli, kova

orion corporation - lenalidomide - kapseli, kova - 5 mg - lenalidomidi

Lenalidomide Fresenius Kabi 25 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide fresenius kabi 25 mg kapseli, kova

fresenius kabi ab - lenalidomide - kapseli, kova - 25 mg - lenalidomidi

Lenalidomide Fresenius Kabi 20 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide fresenius kabi 20 mg kapseli, kova

fresenius kabi ab - lenalidomide - kapseli, kova - 20 mg - lenalidomidi

Lenalidomide Fresenius Kabi 15 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide fresenius kabi 15 mg kapseli, kova

fresenius kabi ab - lenalidomide - kapseli, kova - 15 mg - lenalidomidi

Lenalidomide Fresenius Kabi 10 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide fresenius kabi 10 mg kapseli, kova

fresenius kabi ab - lenalidomide - kapseli, kova - 10 mg - lenalidomidi

Lenalidomide Fresenius Kabi 5 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide fresenius kabi 5 mg kapseli, kova

fresenius kabi ab - lenalidomide - kapseli, kova - 5 mg - lenalidomidi

Lenalidomide Fresenius Kabi 2.5 mg kapseli, kova Fínsko - fínčina - Fimea (Suomen lääkevirasto)

lenalidomide fresenius kabi 2.5 mg kapseli, kova

fresenius kabi ab - lenalidomide - kapseli, kova - 2.5 mg - lenalidomidi

MERON PLUS AC Taliansko - fínčina - Ministero della Salute

meron plus ac

Venclyxto Európska únia - fínčina - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastiset aineet - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Lunsumio Európska únia - fínčina - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfooma, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.